4.7 Article

SLCO4A1-AS1 promotes colorectal tumourigenesis by regulating Cdk2/c-Myc signalling

Journal

JOURNAL OF BIOMEDICAL SCIENCE
Volume 29, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s12929-022-00789-z

Keywords

Colorectal cancer; Long non-coding RNA; Cdk2; c-Myc

Funding

  1. National Natural Science Foundation of China [81972220, 82173063, 81802469]
  2. China Postdoctoral Science Foundation [2020M681493]
  3. Postdoctoral Science Foundation of Jiangsu Province [2020Z050]
  4. Medical Key Professionals Program of Jiangsu Province [ZDRCB2016017]
  5. Wuxi Taihu Lake Talent Plan
  6. Project of Jiangsu Health Committee [LGY2019017]
  7. Top Talent Support Program for young and middle-aged people of Wuxi Health Committee [BJ2020058, HB2020044, BJ2020053]
  8. Project of Wuxi Health Committee [Z202005]
  9. Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX18_1868]

Ask authors/readers for more resources

SLCO4A1-AS1 is upregulated in colorectal cancer (CRC) and associated with poor prognosis. SLCO4A1-AS1 acts as a molecular scaffold to regulate the Hsp90/Cdk2/c-Myc axis and promote the growth of CRC.
Background SLCO4A1-AS1 was found to be upregulated in several cancer types, including colorectal cancer (CRC). However, the detailed roles of SLCO4A1-AS1 in CRC remain to be elucidated. Therefore, we investigated the functions, mechanism, and clinical significance of SLCO4A1-AS1 in colorectal tumourigenesis. Methods We measured the expression of SLCO4A1-AS1 in CRC tissues using qRT-PCR and determined its correlation with patient prognosis. Promoter methylation analyses were used to assess the methylation status of SLCO4A1-AS1. Gain- and loss-of-function assays were used to evaluate the effects of SLCO4A1-AS1 on CRC growth in vitro and in vivo. RNA pull-down, RNA immunoprecipitation, RNA-seq, luciferase reporter and immunohistochemistry assays were performed to identify the molecular mechanism of SLCO4A1-AS1 in CRC. Results SLCO4A1-AS1 was frequently upregulated in CRC tissues based on multiple CRC cohorts and was associated with poor prognoses. Aberrant overexpression of SLCO4A1-AS1 in CRC is partly attributed to the DNA hypomethylation of its promoter. Ectopic SLCO4A1-AS1 expression promoted CRC cell growth, whereas SLCO4A1-AS1 knockdown repressed CRC proliferation both in vitro and in vivo. Mechanistic investigations revealed that SLCO4A1-AS1 functions as a molecular scaffold to strengthen the interaction between Hsp90 and Cdk2, promoting the protein stability of Cdk2. The SLCO4A1-AS1-induced increase in Cdk2 levels activates the c-Myc signalling pathway by promoting the phosphorylation of c-Myc at Ser62, resulting in increased tumour growth. Conclusions Our data demonstrate that SLCO4A1-AS1 acts as an oncogene in CRC by regulating the Hsp90/Cdk2/c-Myc axis, supporting SLCO4A1-AS1 as a potential therapeutic target and prognostic factor for CRC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available